NEW YORK, Dec 13, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Forest Laboratories, Inc.
(NYSE: FRX), announced today that it has received notification from several
companies that they have filed Abbreviated New Drug Applications (ANDA) with
Paragraph IV Certifications to obtain approval to market generic equivalents
of Namenda, an NMDA receptor antagonist indicated for the treatment of
moderate to severe dementia of the Alzheimer's type. The Company intends to
pursue all appropriate legal action to defend its intellectual property
related to Namenda. Namenda is covered by an issued U.S. patent which is set
to expire in April 2010. Forest has applied for patent term restoration
which, if granted, would extend Namenda's patent protection until September
2013.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform act of 1995. These statements involve a number of
risks and uncertainties, including the difficulty of predicting FDA approvals,
the acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in each of Forest
Laboratories' Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and
any subsequent SEC filings.
SOURCE Forest Laboratories, Inc.
http://www.frx.com/